Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Transplantation ; 72(2): 209-15, 2001 Jul 27.
Article in English | MEDLINE | ID: mdl-11477340

ABSTRACT

BACKGROUND: Low-molecular-weight heparin (LMWH) has been shown to prolong survival of rat cardiac allografts independently from immunosuppressive treatment. Furthermore, long-term treatment reduces the development of chronic graft vascular disease after experimental heart transplantation. The aim of the present study was to determine whether treatment with the LMWH reviparin has a beneficial effect on chronic rejection in a rat renal allograft model. METHODS: Kidneys of Fisher (F344) rats were transplanted into unilaterally nephrectomized Lewis (LEW) recipients. LEW-->LEW isografts served as controls. Animals were treated with cyclosporine (5 mg/kg/d) for the first 10 days. Nephrectomy of the remaining kidney was performed after 10 days. Allografted animals were treated either with reviparin (2 mg/kg/d subcutaneously) for 24 weeks (Allo-24), from week 12 to 24 (Allo-12), or with vehicle for 24 weeks. Proteinuria was determined at regular intervals. Kidneys were harvested after 24 weeks for histomorphological and immunohistochemical evaluation. RESULTS: No major bleeding complications were observed in reviparin-treated animals. Proteinuria was significantly reduced in allografted animals both by early as well as by late-onset treatment with reviparin. Transplant glomerulopathy was diminished in Allo-24 and in Allo-12 groups compared to vehicle-treated animals, whereas tubulointerstitial inflammation was influenced only in animals immediately treated with reviparin. Immunohistochemical studies demonstrated a marked reduction of renal monocyte and T-cell infiltration as well as expression of MHC II by treatment with reviparin. CONCLUSIONS: Treatment with the LMWH reviparin significantly improved chronic renal allograft rejection in the F344-to-LEW rat model, both after early and late start of therapy. Although the exact mechanisms of this beneficial effect remain unclear, our data offer a potential new therapeutical approach for prevention of chronic allograft nephropathy.


Subject(s)
Graft Rejection/drug therapy , Heparin, Low-Molecular-Weight/therapeutic use , Kidney Transplantation/immunology , Animals , Anticoagulants/therapeutic use , Chronic Disease , Cyclosporine/therapeutic use , Graft Rejection/pathology , Histocompatibility Antigens Class II/analysis , Kidney Transplantation/pathology , Kidney Transplantation/physiology , Male , Proteinuria , Rats , Rats, Inbred F344 , Rats, Inbred Lew , Systole/drug effects , T-Lymphocytes/pathology , Time Factors , Transplantation, Homologous , Transplantation, Isogeneic
3.
J Cardiovasc Pharmacol ; 36(4): 428-37, 2000 Oct.
Article in English | MEDLINE | ID: mdl-11026642

ABSTRACT

A markedly increased expression of endothelin (ET)-1 has been observed in renal allografts with chronic rejection, one of the most common causes of kidney graft loss. In this study we investigated the effect of treatment with a combined ET-A/B-receptor antagonist on the course of chronic renal allograft rejection. Experiments were performed in the Fisher-to-Lewis rat model of chronic rejection. Lewis-to-Lewis isografts and uninephrectomized Lewis rats served as controls. Animals were treated with either the oral combined ET-A/B-receptor antagonist LU224332 (20 mg/kg/day) or vehicle. Animal survival, blood pressure, creatinine clearance, proteinuria, and urinary ET excretion were investigated for 24 weeks. Kidneys were removed for light-microscopic evaluation and immunohistochemical assessment of cell-surface markers. Treatment with LU224332 did not improve survival after 24 weeks (0.47 vs. 0.38; p > 0.05 by log-rank test), nor did it have an influence on blood pressure, creatinine clearance, or proteinuria. Combined ET-A/B-receptor blockade was associated with a reduction of expression of cell-surface markers for macrophages (EDI), T-cells (R73), and major histocompatibility complex (MHC) II (F17-23-2), but did not lead to an improvement of histologic changes of chronic allograft rejection. Our data show that blocking both ET-A- and -B receptors, in opposition to a previously published beneficial effect of selective ET-A blockade, does not prevent the progression of chronic renal allograft rejection and does not prolong survival in this model. Functional integrity of the ET-B receptor therefore seems to play an important role in the nephroprotection provided by selective ET-A-receptor antagonists in chronic renal allograft nephropathy.


Subject(s)
Endothelin Receptor Antagonists , Graft Rejection/prevention & control , Kidney Transplantation/physiology , Propionates/therapeutic use , Pyrimidines/therapeutic use , Animals , Blood Pressure/drug effects , Chronic Disease , Creatinine/urine , Endothelins/urine , Genes, MHC Class II , Graft Rejection/pathology , Graft Survival/drug effects , Immunohistochemistry , Kidney/pathology , Male , Proteinuria/chemically induced , Rats , Rats, Inbred F344 , Rats, Inbred Lew , Receptor, Endothelin A , Receptor, Endothelin B
4.
Transplantation ; 68(6): 739-46, 1999 Sep 27.
Article in English | MEDLINE | ID: mdl-10515373

ABSTRACT

BACKGROUND: Chronic rejection is the most common cause of graft loss in renal transplantation. The pathomechanisms underlying chronic rejection are poorly understood, and no treatment has yet successfully been established. We hypothesized that, in analogy to models of reduced renal mass, the administration of a selective endothelin (ET) A receptor antagonist could improve the course of chronic rejection in renal allografts. METHODS: Experiments were performed in the Fisher-to-Lewis rat model of chronic rejection. Lewis-->Lewis isografts served as controls. Animals were treated with either the oral selective ET-A receptor antagonist LU135252 (50 mg/kg/day) or vehicle. Animal survival, blood pressure, creatinine clearance, proteinuria, and urinary ET excretion were investigated for 24 weeks. Kidneys were removed for light microscopical evaluation, determination of ET mRNA expression and tissue protein concentration, and immunohistochemical assessment of cell surface markers. RESULTS: Rats with chronic rejection showed an increase in renal ET mRNA synthesis and ET protein content. Treatment with LU135252 resulted in a significant improvement in survival after 24 weeks (0.92 vs. 0.38, P<0.01 by log-rank test). Creatinine clearance was higher in animals treated with the selective ET-A receptor antagonist (P<0.05). LU135252 had no influence on blood pressure and proteinuria. Selective ET-A blockade was associated with significantly less morphological changes and a significant reduction of expression of cell surface markers for macrophages (ED1), T cells (R73), and MHC II (F17-23-2). CONCLUSION: The renal ET-A system plays an important role in the pathomechanisms underlying chronic renal allograft rejection, because the treatment with a selective ET-A receptor antagonist dramatically improves the course of chronic renal failure after allograft transplantation. These results offer a novel therapeutical option for treatment of chronic renal allograft rejection, for which so far no therapy is known.


Subject(s)
Endothelin Receptor Antagonists , Kidney Transplantation/immunology , Administration, Oral , Animals , Endothelin-1/genetics , Endothelins/urine , Graft Rejection/prevention & control , Graft Survival/drug effects , Kidney Diseases/prevention & control , Kidney Glomerulus/drug effects , Male , Phenylpropionates/therapeutic use , Pyrimidines/therapeutic use , RNA, Messenger/metabolism , Rats , Rats, Inbred F344 , Rats, Inbred Lew , Receptor, Endothelin A , Receptors, Endothelin/administration & dosage
SELECTION OF CITATIONS
SEARCH DETAIL
...